Corrigendum to: Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes (Diabetes Obes Metab, (2016), 18, (266–273), 10.1111/dom.12608);Ten-year observational follow-up of PROactive: A randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 18, Issue 3, 2016, Pages 266-273

  Erdmann, E ^a   Harding, S ^b   Lam, H ^c   Perez, A ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Takeda Global Research and Development Centre Europe   (United Kingdom)

^c TAKEDA DEVELOPMENT CENTER AMERICAS   (United States)

Author keywords

Glucose lowering drug; Macrovascular disease; Phase IV study; PPAR gamma agonist; Thiazolidinediones; Type 2 diabetes

Indexed keywords

PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ARTICLE; BLADDER CANCER; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FOLLOW UP; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; LEG AMPUTATION; LEG REVASCULARIZATION; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PROSTATE CANCER; TREND STUDY; AGED; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE BLIND PROCEDURE; FEMALE; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; URINARY BLADDER NEOPLASMS;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84957848154     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12965     Document Type: Erratum

References (33)

1. Charbonnel B, Dormandy J, Erdmann E etal. The prospective pioglitazone clinical trial in macrovascular events (PROactive): Can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Diabetes Care 2004; 27: 1647-1653.
2. Dormandy JA, Charbonnel B, Eckland DJA etal., PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
3. Erdmann E, Dormandy JA, Charbonnel B, PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2, 445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780.
4. Wilcox R, Bousser M-G, Betteridge DJ etal, PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873.
5. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A-R, PROactive Investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
6. Erdmann E, Dormandy JA, Massi-Benedetti M, Spanheimer R. Pioglitazone and bladder cancer - Authors' reply. Lancet 2011; 378: 1544-1545.
7. Erdmann E, Song E, Spanheimer R, van Troostenburg de Bruyn A-R, Perez A. Observational follow-up of the PROactive study: a 6-year update. Diabetes Obes Metab 2014; 16: 63-74.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.
9. Dormandy JA, Betteridge DJ, Schernthaner G etal. Impact of peripheral arterial disease in patients with diabetes-results from PROactive (PROactive 11). Atherosclerosis 2009; 202: 272-281.
10. Zoungas S, Chalmers J, Neal B, on behalf of the ADVANCE-ON Collaborative Group. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 2014; 371: 1392-1406.
11. Ramos-Nino ME, MacLean CD, Littenberg B. Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System. BMC Med 2007; 5: 17.
12. van Staa TP, Patel D, Gallagher AM, de Bruin ML. Glucose-lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012; 55: 654-665.
13. Govindarajan R, Ratnasinghe L, Simmons DL etal. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007; 25: 1476-1481.
14. Koro C, Barrett S, Qizilbash N. Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf 2007; 16: 485-492.
15. Oliveria SA, Koro CE, Yood MU, Sowell M. Cancer incidence among patients treated with antidiabetic pharmacotherapy. Diabetes Metab Syndr Clin Res Rev 2008; 2: 47-57.
16. Ferrara A, Lewis JD, Quesenberry CP Jr etal. Cohort study of pioglitazone and cancer incidence in patients with diabetes. Diabetes Care 2011; 34: 923-929.
17. Matsumoto K, Irie A, Satoh T etal. Occupational bladder cancer: from cohort study to biologic molecular marker. Med Sci Monit 2005; 11: RA311-RA315.
18. Ryder REJ, Controversies in Diabetes. Neither evidence from the PROactive study nor the KPNC supports pioglitazone as a tumour promoter. Diabet Med 2015; 32: 438-439.
19. FirstWord Pharma. Completion of the post-marketing commitment to submit data to the FDA, 28 August 2014. Available from URL: http://www.firstwordpharma.com/node/1232261#axzz3BlGF2JfP. Accessed 8 August 2015.
20. Lewis JD, Habel LA, Quesenberry CP etal. Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 2015; 314: 265-277.
21. Levin D, Bell S, Sund R etal. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 2015; 58: 493-504.
22. Korhonen P, Heintjes EM, Williams R etal. Bladder cancer risk in relation to exposure to pioglitazone among patients with T2DM in the Pan European Multi-Database Bladder Cancer Risk Characterisation Study. Presentation 169-LB, ADA 75th Scientific Session, Boston, 5-9 June 2015.
23. Balaji V, Seshiah V, Ashtalakshmi RSG, Jananrthinakani M. A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population. Indian J Endocrinol Metab 2014; 18: 425-427.
24. Fujimoto K, Hamamoto Y, Honjo S etal. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013; 99: e21-e23.
25. Song SO, Kim KL, Lee BW, Kang ES, Cha BS, Lee HC. The risk of bladder cancer in Korean diabetic subjects treated with pioglitazone. Diabetes Metab J 2012; 36: 371-378.
26. Tseng CH. Pioglitazone and Bladder Cancer: A population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
27. Kuo HW, Tiao MM, Ho SC, Yang CY. Pioglitazone use and the risk of bladder cancer. Kaohsiung J Med Sci 2014; 30: 94-97.
28. Wei L, MacDonald TM, Mackensie IS. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013; 75: 254-259.
29. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-1962.
30. Hsiao FY, Hsieh PH, Huang WF, Tsai YW, Gau CS. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf 2013; 36: 643-649.
31. Azoulay L, Yin H, Filion KB etal. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
32. Jin SM, Song SO, Jung CH etal. Risk of bladder cancer among patients with diabetes treated with a 15mg pioglitazone dose in Korea: a multi-center retrospective cohort study. J Korean Med Sci 2014; 29: 238-242.
33. Fröhlich E, Wahl R. Chemotherapy and chemoprevention by thiazolidinediones. Biomed Res Int 2015; 2015: 845340.